{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:49:15Z","timestamp":1793137755735,"version":"4.5.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Urticarial vasculitis is a rare condition manifesting with a variety of clinical presentations ranging from skin limited lesions to life-threatening systemic illnesses. This review aims to highlight the recent findings on the etiology, diagnostic modalities, and therapeutic strategies and course of urticarial vasculitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In addition to well established triggers, urticarial vasculitis (UV) cases associated with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) disease and COVID-19 vaccines, vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome, and adenosine deaminase (ADA) deficiency have been reported. A clinical-dermoscopic model for differentiating urticarial vasculitis has been developed with purpuric patches and globules favoring UV diagnosis and thus diminishing the need for histopathology. The efficacy of treatment modalities has been reviewed, and antihistamines, systemic corticosteroids, omalizumab, cyclophosphamide, tocilizumab, anti-interleukin (IL)-1 agents, and rituximab were shown to have the highest success rates. Regarding the durability of remission, rituximab, dapsone, and MMF were related to long-lasting treatment free responses. The course of hypocomplementemic urticarial vasculitis was investigated in an epidemiological study, revealing 5- and 10-year survival rates of 92% and 83%, respectively. Chronic obstructive pulmonary disease, septicemia, and end-stage renal disease were identified as causes of mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>With the aid of dermoscopy, a noninvasive tool, differentiation from chronic spontaneous urticaria can be made, and the need for histopathological examination can be diminished. Although clear definitions and consensus criteria for performing disease severity are lacking, careful screening is needed to tailor the treatment on an individual basis. Emerging infections like SARS-CoV 2, vaccines, and autoinflammatory disorders like VEXAS syndrome and ADA deficiency are new associations. The optimal use of well established agents like systemic corticosteroids and immunomodulators are mainstay treatment modalities, whereas IL-1 inhibitors, omalizumab, rituximab and Janus Kinase inhibitors may represent viable alternatives in selected cases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001058","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:00:15Z","timestamp":1728907215000},"page":"45-50","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Urticarial vasculitis"],"prefix":"10.1097","volume":"37","author":[{"given":"T\u00fclin","family":"Ergun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2500\/aap.2007.28.2972","article-title":"Urticarial vasculitis","volume":"28","author":"Chang","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/CRIAI:23:2:201","article-title":"Urticarial vasculitis","volume":"23","author":"Venzor","year":"2002","journal-title":"Clin Rev Allergy Immunol"},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2230.1996.tb00146.x","article-title":"Consensus meeting on the definition of physical urticarias and urticarial vasculitis","volume":"21","author":"Black","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.40375","article-title":"Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"70","author":"Sunderk\u20acotter","year":"2018","journal-title":"Arthritis Rheum"},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.iac.2004.01.007","article-title":"Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome","volume":"24","author":"Davis","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/rheumatology\/key110","article-title":"Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis)","volume":"57","author":"Sj\u00f6wall","year":"2018","journal-title":"Rheumatology"},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12882-022-02689-8","article-title":"Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis","volume":"23","author":"Corthier","year":"2022","journal-title":"BMC Nephrol"},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1016\/j.jaip.2022.07.003","article-title":"In urticarial vasculitis, long disease duration, high symptom burden, and high need for therapy are linked to low patient-reported quality of life","volume":"10","author":"Bonnekoh","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R10-20250108","first-page":"340","article-title":"Hypocomplementemia with cutaneous vasculitis and arthritis: possible immune complex syndrome","volume":"48","author":"McDuffie","year":"1973","journal-title":"Mayo Clin Proc"},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/archderm.134.1.88","article-title":"Pathophysiology of urticarial vasculitis","volume":"134","author":"Mehregan","year":"1998","journal-title":"Arch Dermatol"},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3389\/fimmu.2018.00639","article-title":"Complement activation in inflammatory skin diseases","volume":"9","author":"Giang","year":"2018","journal-title":"Front Immunol"},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/14740338.2.4.401","article-title":"Drug-induced vasculitis","volume":"2","author":"Doyle","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40413-015-0059-y","article-title":"Urticarial vasculitis induced by OTC diet pills: a case report","volume":"8","author":"Ch\u00e9rrez Ojeda","year":"2015","journal-title":"World Allergy Organ J"},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2133.1995.tb00734.x","article-title":"Hypocomplementaemic urticarial vasculitis, interstitial lung disease and hepatitis C","volume":"132","author":"Lin","year":"1995","journal-title":"Br J Dermatol"},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0190-9622(08)81019-5","article-title":"Urticarial vasculitis and Lyme disease","volume":"22","author":"Olson","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"R17-20250108","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0002-9343(76)90436-8","article-title":"Circulating immune complexes and complement sequence activation in infectious mononucleosis","volume":"60","author":"Wands","year":"1976","journal-title":"Am J Med"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-98-2-155","article-title":"Sj\u00f6gren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity","volume":"98","author":"Alexander","year":"1983","journal-title":"Ann Intern Med"},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0049-0172(91)90029-Y","article-title":"Urticarial vasculitis in a connective tissue disease clinic: patterns, presentations, and treatment","volume":"20","author":"Asherson","year":"1991","journal-title":"Semin Arthritis Rheum"},{"key":"R20-20250108","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/1529-0131(199806)41:6<1133::AID-ART23>3.0.CO;2-S","article-title":"Cutaneous vasculitis as a paraneoplastic syndrome in adults","volume":"41","author":"Garc\u00eda-Porr\u00faa","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R21-20250108","first-page":"652","article-title":"Primary Sj\u00f6gren's syndrome: clinical and immunologic study of 80 patients","volume":"108","author":"Ramos","year":"1997","journal-title":"Med Clin"},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2340\/0001555570345347","article-title":"Urticarial vasculitis occurring in association with visceral malignancy","volume":"70","author":"Lewis","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"R23-20250108","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1111\/jdv.16713","article-title":"Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom?","volume":"34","author":"de Perosanz-Lobo","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"e04323","DOI":"10.1002\/ccr3.4323","article-title":"SARS-CoV-2 infection as a potential triggering factor for urticarial vasculitis during pregnancy: a case report","volume":"9","author":"Shahidi Dadras","year":"2021","journal-title":"Clin Case Rep"},{"key":"R25-20250108","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/ijd.15112","article-title":"Urticarial vasculitis in a COVID-19 recovered patient","volume":"59","author":"Nasiri","year":"2020","journal-title":"Int J Dermatol"},{"key":"R26-20250108","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1111\/jdv.17391","article-title":"Urticarial vasculitis revealing immunolabelled nucleocapsid protein of SARS-CoV-2 in two Brazilian asymptomatic patients: the tip of the COVID-19 hidden iceberg?","volume":"35","author":"Criado","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.42411","article-title":"The characteristics of patients with COVID-19-associated pediatric vasculitis: an international, multicenter study","volume":"75","author":"Batu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/1346-8138.16651","article-title":"Cutaneous manifestations of COVID-19 and COVID-19 vaccination","volume":"50","author":"Nakashima","year":"2023","journal-title":"J Dermatol"},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"e15613","DOI":"10.1111\/dth.15613","article-title":"Urticarial vasculitis after COVID-19 vaccination: a case report and literature review","volume":"35","author":"Ono","year":"2022","journal-title":"Dermatol Ther"},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"678927","DOI":"10.3389\/fimmu.2021.678927","article-title":"VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome","volume":"12","author":"Staels","year":"2021","journal-title":"Front Immunol"},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/ijd.16635","article-title":"Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings","volume":"62","author":"Hines","year":"2023","journal-title":"Int J Dermatol"},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"e12305","DOI":"10.1002\/clt2.12305","article-title":"Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: an international Delphi survey","volume":"13","author":"Krause","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1038\/s41598-020-63146-w","article-title":"Development of a clinical-dermoscopic model for the diagnosis of urticarial vasculitis","volume":"10","author":"Garcia","year":"2020","journal-title":"Sci Rep"},{"key":"R34-20250108","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/ijd.14387","article-title":"Eosinophilic infiltration: an underreported histopathological finding in urticarial vasculitis","volume":"58","author":"Kamyab","year":"2019","journal-title":"Int J Dermatol"},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0272-6386(99)70402-6","article-title":"Hypocomplementemic urticarial vasculitis or systemic lupus erythematosus?","volume":"34","author":"Trendelenburg","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"R36-20250108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40257-022-00736-6","article-title":"Cutaneous small vessel vasculitis: a practical guide to diagnosis and management","volume":"24","author":"Micheletti","year":"2023","journal-title":"Am J Clinical Dermatol"},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijwd.2021.01.021","article-title":"Urticarial vasculitis","volume":"7","author":"Gu","year":"2021","journal-title":"Int J Womens Dermatol"},{"issue":"(Pt 2)","key":"R38-20250108","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0190-9622(92)70069-R","article-title":"Urticarial vasculitis: a histopathologic and clinical review of 72 cases","volume":"26","author":"Mehregan","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"R39-20250108","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2024.03.006","article-title":"Urticarial vasculitis","volume":"44","author":"Wang","year":"2024","journal-title":"Immunol Allergy Clin N Am"},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.38956","article-title":"The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from French nationwide study of fifty-seven patients","volume":"67","author":"Jachiet","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R41-20250108","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaci.2018.09.007","article-title":"Treatment of urticarial vasculitis: a systematic review","volume":"143","author":"Kolkhir","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R42-20250108","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.jaip.2020.02.024","article-title":"Response of omalizumab in normocomplementemic urticarial vasculitis","volume":"8","author":"Chen","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R43-20250108","doi-asserted-by":"crossref","first-page":"952079","DOI":"10.3389\/falgy.2022.952079","article-title":"Efficacy and safety of omalizumab therapy in urticaria vasculitis","volume":"3","author":"Petrelli","year":"2022","journal-title":"Front Allergy"},{"key":"R44-20250108","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ced\/llad192","article-title":"Successful treatment of urticarial vasculitis with omalizumab in children: a case series","volume":"48","author":"Wang","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"R45-20250108","doi-asserted-by":"crossref","first-page":"e15932","DOI":"10.1111\/dth.15932","article-title":"Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis","volume":"35","author":"Mansouri","year":"2022","journal-title":"Dermatol Ther"},{"key":"R46-20250108","doi-asserted-by":"crossref","first-page":"695768","DOI":"10.3389\/fimmu.2021.695768","article-title":"Tofacitinib treatment of refractory cutaneous leukocytoclastic vasculitis: a case report","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"R47-20250108","doi-asserted-by":"crossref","first-page":"e15780","DOI":"10.1111\/dth.15780","article-title":"Tofacitinib for the treatment of refractory or glucocorticoid-dependent cutaneous leukocytoclastic vasculitis","volume":"35","author":"Ma","year":"2022","journal-title":"Dermatol Ther"},{"key":"R48-20250108","doi-asserted-by":"crossref","first-page":"rkad049","DOI":"10.1093\/rap\/rkad049","article-title":"Tofacitinib as monotherapy in cutaneous polyarteritis nodosa: a case series","volume":"7","author":"Roy","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"R49-20250108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/ajd.13995","article-title":"Treatment-resistant systemic lupus erythematosus-associated hypocomplementic urticarial vasculitis successfully treated with belimumab","volume":"64","author":"Leal","year":"2023","journal-title":"Australas J Dermatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:07:48Z","timestamp":1736334468000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001058","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}